Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
But the company spent millions successfully lobbying for legislation that would authorize Medicare to cover the test beginning in 2028 if the F.D.A. approves it.
Simplified Text
Grail spent millions successfully lobbying for legislation that would authorize Medicare to cover the Galleri test starting in 2028, contingent on FDA approval.
Confidence Score
1.000
Claim Maker
The author
Context Type
News Article
Context Details
{
    "policy": "Medicare coverage for Galleri test",
    "company": "Grail",
    "organization": "Medicare"
}
Subject Tags
Politics Finance Regulation Lobbying
UUID
2f0f59cd-bcf2-4b31-8320-d3883ea127ea
Vector Index
✗ No vector
Created
September 25, 2026 at 1:05 AM (2 weeks ago)
Last Updated
September 25, 2026 at 1:05 AM (2 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/23/well/fda-cancer-blood-test-galleri-grail.html
F.D.A. Advisory Panel Endorses Controversial Cancer Blood Test
Completed News
5 claims
2 weeks ago
https://nytimes.com/2026/09/23/well/fda-cancer-blood-test-galleri-grail.html

An FDA advisory committee recommended approval for Grail's Galleri blood test, designed to detect various cancers early, despite concerns from doctors about its efficacy and lack of data showing reduced cancer deaths. The test has been available since 2021, but experts warn of risks like overdiagnosis and false positives.

FDA Cancer Screening Blood Tests Medical Technology Health Policy Oncology Grail Galleri

Similar Claims (5)

Other claims identified as semantically similar to this one.